Phase 2 Geographic Atrophy Clinical Trials
19 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–19 of 19 trials
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy secondary to Age Related Macular Degeneration
Novartis Pharmaceuticals272 enrolled16 locationsNCT07441642
Recruiting
Phase 2
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Geographic AtrophyMacular Degeneration
Janssen Research & Development, LLC274 enrolled104 locationsNCT06635148
Recruiting
Phase 1Phase 2
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
Geographic Atrophy secondary to Age Related Macular Degeneration
Complement Therapeutics75 enrolled4 locationsNCT07392255
Recruiting
Phase 1Phase 2
A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy secondary to Age Related Macular Degeneration
Kriya Therapeutics, Inc.62 enrolled3 locationsNCT06765980
Recruiting
Phase 2
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Geographic Atrophy secondary to Age Related Macular Degeneration
ADARx Pharmaceuticals, Inc.240 enrolled24 locationsNCT06990269
Recruiting
Phase 1Phase 2
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy
Sanofi104 enrolled17 locationsNCT07215234
Recruiting
Phase 2
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
Geographic Atrophy
Genentech, Inc.60 enrolled17 locationsNCT05626114
Recruiting
Phase 2
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
Geographic Atrophy secondary to Age Related Macular Degeneration
Apellis Pharmaceuticals, Inc.240 enrolled43 locationsNCT07215390
Recruiting
Phase 2
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
Geographic AtrophyDry Age-Related Macular Degeneration
Regenerative Patch Technologies, LLC24 enrolled5 locationsNCT06557460
Recruiting
Phase 1Phase 2
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Geographic AtrophyAge-Related Macular Degeneration
AbbVie66 enrolled4 locationsNCT07160179
Recruiting
Phase 2
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Geographic Atrophy of the Macula
Galimedix Therapeutics Inc110 enrolled14 locationsNCT06659549
Recruiting
Phase 1Phase 2
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Geographic AtrophyDry Age-Related Macular Degeneration
National Eye Institute (NEI)20 enrolled2 locationsNCT04339764
Recruiting
Phase 1Phase 2
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD
Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Bionic Sight LLC40 enrolled1 locationNCT07158775
Recruiting
Phase 2
SGLT2 Inhibitors in Geographic Atrophy
Geographic AtrophyRetinal diseasesRetinal Degeneration+2 more
Washington University School of Medicine70 enrolled1 locationNCT07174687
Recruiting
Phase 2
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Age related macular degeneration (AMD)Geographic Atrophy (GA)
ONL Therapeutics324 enrolled28 locationsNCT06659445
Recruiting
Phase 1Phase 2
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Geographic AtrophyAge-Related Macular DegenerationNon-neovascular AMD
Perceive Biotherapeutics, Inc.60 enrolled11 locationsNCT06087458
Recruiting
Phase 1Phase 2
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
Geographic AtrophyAge-Related Macular DegenerationMacular Degeneration+2 more
Eyestem Research Pvt. Ltd.54 enrolled3 locationsNCT06394232
Not Yet Recruiting
Phase 2
A Phase II, Multicentre, 2-part, Study of the Safety, Tolerability, and Efficacy of Intravitreal Fludrocortisone Acetate in Subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration - Part B
Geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
EyeCo Pty Ltd126 enrolled1 locationACTRN12624000997550
Active
Phase 2
A Phase II, Multicentre, 2-part, Study of the Safety, Tolerability, and Efficacy of Intravitreal Fludrocortisone Acetate in Subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
EyeCo Pty Ltd9 enrolled1 locationACTRN12624000971538